• Brainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -75 cents. The lone analyst forecast for the quarter was for a loss of 97 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Brainstorm Cell Therapeutics Inc's reported EPS for the quarter was a loss of 45 cents​.

• The company reported a quarterly loss of $2.86 million.

• Brainstorm Cell Therapeutics Inc shares had fallen by 9.5% this quarter and lost 49.8% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Brainstorm Cell Therapeutics Inc is $14.26

This summary was machine generated from LSEG data May 15 at 08:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)